Nathalie Roxanne Javidi-Sharifi, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2021 | 38 | 0.810 |
Why?
|
| Fibroblast Growth Factor 2 | 3 | 2019 | 599 | 0.700 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 250 | 0.610 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2014 | 105 | 0.510 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2018 | 776 | 0.490 |
Why?
|
| Exosomes | 1 | 2019 | 417 | 0.480 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2018 | 643 | 0.430 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2021 | 5535 | 0.360 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2019 | 1632 | 0.320 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2019 | 3523 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11524 | 0.190 |
Why?
|
| Niacinamide | 1 | 2021 | 417 | 0.170 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 13695 | 0.170 |
Why?
|
| Signal Transduction | 3 | 2023 | 23403 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2018 | 5172 | 0.140 |
Why?
|
| GTP-Binding Protein beta Subunits | 1 | 2014 | 33 | 0.130 |
Why?
|
| Receptor Cross-Talk | 1 | 2014 | 119 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 2938 | 0.110 |
Why?
|
| Drug Discovery | 1 | 2021 | 1058 | 0.110 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2016 | 491 | 0.110 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 905 | 0.100 |
Why?
|
| Pyridazines | 1 | 2014 | 202 | 0.100 |
Why?
|
| Benzamides | 2 | 2014 | 1379 | 0.100 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2014 | 474 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2021 | 1972 | 0.100 |
Why?
|
| Drug Synergism | 1 | 2014 | 1792 | 0.090 |
Why?
|
| GTP-Binding Proteins | 1 | 2014 | 970 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1655 | 0.090 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 3505 | 0.090 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 689 | 0.080 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 16689 | 0.080 |
Why?
|
| Cell Survival | 1 | 2019 | 5882 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2014 | 931 | 0.080 |
Why?
|
| Imidazoles | 1 | 2014 | 1206 | 0.080 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 1526 | 0.070 |
Why?
|
| Piperazines | 2 | 2014 | 2488 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2014 | 2942 | 0.070 |
Why?
|
| HEK293 Cells | 1 | 2014 | 4204 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 2942 | 0.060 |
Why?
|
| Mice, Knockout | 1 | 2019 | 14557 | 0.060 |
Why?
|
| Mutation | 4 | 2018 | 29786 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2014 | 8436 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2019 | 19229 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2018 | 7880 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2023 | 2503 | 0.050 |
Why?
|
| Melanoma | 1 | 2018 | 5510 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 18029 | 0.040 |
Why?
|
| Mice | 3 | 2019 | 81183 | 0.040 |
Why?
|
| Humans | 8 | 2023 | 744343 | 0.030 |
Why?
|
| Neoplasms | 1 | 2023 | 21683 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2023 | 2109 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2014 | 203 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2014 | 146 | 0.030 |
Why?
|
| Tumor Microenvironment | 2 | 2016 | 3586 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 434 | 0.030 |
Why?
|
| K562 Cells | 1 | 2014 | 634 | 0.030 |
Why?
|
| Animals | 3 | 2019 | 168757 | 0.030 |
Why?
|
| Janus Kinase 2 | 1 | 2014 | 528 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 3557 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2014 | 1285 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1692 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 8428 | 0.010 |
Why?
|